Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.75 USD
Change Today +0.14 / 8.70%
Volume 856.5K
DRRX On Other Exchanges
As of 5:20 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

durect corporation (DRRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/30/14 - $1.89
52 Week Low
10/27/14 - $0.68
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DURECT CORPORATION (DRRX)

durect corporation (DRRX) Related Businessweek News

No Related Businessweek News Found

durect corporation (DRRX) Details

DURECT Corporation, a specialty pharmaceutical company, is engaged in the development of pharmaceutical products based on its proprietary drug delivery technology platforms in the United States and internationally. It focuses on the development of various products for the treatment of various chronic and episodic disease areas, such as pain, central nervous system disorders, metabolic disorders, cardiovascular disease, and other chronic diseases. The company’s products comprise ALZET product line that consists of osmotic pumps and accessories, which are used for experimental research in mice, rats, and other laboratory animals; and a range of standard and custom biodegradable polymers that are used as raw materials in the pharmaceutical and medical devices under the brand name of LACTEL. Its products also include REMOXY, an oral oxycodone gelatin capsule for chronic pain; POSIDUR, a formulation of bupivacaine for the treatment of post-surgical pain that has completed Phase III clinical study; ELADUR, a Phase II transdermal bupivacaine patch intended to provide delivery of bupivacaine; and TRANSDUR-Sufentanil that has completed Phase II transdermal sufentanil patch, which is intended to provide delivery of sufentanil. In addition, the company’s products pipeline comprises ORADUR-based opioids, including hydrocodone and hydromorphone that are in Phase I clinical trials for the treatment of pain; oxymorphone, an ORADUR-based opioid for which IND has been accepted by the FDA; ORADUR-ADHD, a drug candidate in Phase I clinical trial for the treatment of attention deficit hyperactivity disorder; and Relday, an injectable risperidone product in Phase I clinical trial used to treat the symptoms of schizophrenia and bipolar I disorder. It has strategic agreements with various companies, such as Pain Therapeutics, Inc.; Pfizer Inc.; Zogenix, Inc.; Hospira, Inc.; and Nycomed Danmark ApS. The company was founded in 1998 and is headquartered in Cupertino, California.

102 Employees
Last Reported Date: 03/3/15
Founded in 1998

durect corporation (DRRX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $450.7K
Co-Founder, Chairman and Chief Scientific Off...
Total Annual Compensation: $248.2K
Chief Financial Officer
Total Annual Compensation: $310.5K
Executive Vice President of Pharmaceutical Sy...
Total Annual Compensation: $298.2K
Compensation as of Fiscal Year 2013.

durect corporation (DRRX) Key Developments

DURECT Corporation Announces Successful Completion of Phase 1 Study on Potential Liver Disease and Steatohepatitis Treatment

DURECT Corporation announced that a Phase 1 clinical trial on DUR-928 was completed successfully, noting that the drug was well-tolerated at all dose levels, with no treatment-related adverse events reported and no subjects withdrawing from the study. DUR-928 is a new chemical entity (NCE) that may have broad applicability as a treatment of metabolic diseases such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and in acute organ injuries such as acute kidney injury.

DURECT Corporation Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

DURECT Corporation reported unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of $4.269 million compared to $4.289 million for the same period a year ago. Loss from operations was $5.355 million compared to $5.092 million for the same period a year ago. Net loss was $5.940 million or $0.05 per diluted share compared to $5.1 million or $0.05 per diluted share for the same period a year ago. For the year, the company reported total revenues of $19.401 million compared to $15.326 million for the same period a year ago. Loss from operations was $20.998 million compared to $21.162 million for the same period a year ago. Net loss was $22.110 million or $0.20 per diluted share compared to $21.452 million or $0.21 per diluted share for the same period a year ago.

DURECT Corporation to Report Q4, 2014 Results on Mar 02, 2015

DURECT Corporation announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Mar 02, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRRX:US $1.75 USD +0.14

DRRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cosmo Pharmaceuticals SA SFr.167.00 CHF -2.20
Elite Pharmaceuticals Inc $0.23 USD -0.0045
Pacira Pharmaceuticals Inc/DE $91.11 USD +1.19
Supernus Pharmaceuticals Inc $11.32 USD +0.65
Veloxis Pharmaceuticals A/S kr0.86 DKK -0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation DRRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.4x
Price/Book 9.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DURECT CORPORATION, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at